Literature DB >> 29472821

Thrombotic thrombocytopenic purpura in the course of systemic lupus erythematosus in a 15-year-old girl.

Hanna Szymanik-Grzelak1, Joanna Przychodzeń1, Anna Stelmaszczyk-Emmel2, MaŁgorzata Pańczyk-Tomaszewska1.   

Abstract

Systemic lupus erythematosus (SLE) concomitant with thrombotic thrombocytopenic purpura (TTP) in children is rarely diagnosed. We report a case of a 15-year-old girl with butterfly patch, generalized edema, leg pain, anemia (Hb 74 g/l), thrombocytopenia (5 x 109/l), schistocytes in peripheral blood smear, acute kidney injury (eGFR 27 ml/min/1.73 m2), proteinuria, and erythrocyturia. The direct Coombs test was positive, and warm antibodies (IgG) were detected on red blood cells. ANA in titer 1 : 2560, low serum C3 and C4 complement level, ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity < 4% and the presence of ADAMTS13 inhibitor were detected. In renal biopsy class IVA/V lupus nephritis was diagnosed. Her clinical symptoms fulfilled criteria for the diagnosis of SLE and the diagnosis of TTP. She was treated with intravenous methylprednisolone and cyclophosphamide 750 mg/1.73 m2/monthly for six months, followed by oral prednisone with azathioprine, chloroquine, and enalapril. The long-term clinical outcome was good. We report a case rare in adolescents, TTP related to SLE, which may suggest the need to test for ADAMTS13 activity and the presence of ADAMTS13 inhibitor in children with SLE and anemia, thrombocytopenia and rapid deterioration of renal function, to make the right therapeutic decisions.

Entities:  

Keywords:  ADAMTS13; children; hemolytic-uremic syndrome; lupus nephritis; thrombotic thrombocytopenic purpura

Year:  2017        PMID: 29472821      PMCID: PMC5820984          DOI: 10.5114/ceji.2017.72822

Source DB:  PubMed          Journal:  Cent Eur J Immunol        ISSN: 1426-3912            Impact factor:   2.085


Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease with multiple manifestations and varying clinical severity [1]. Hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are forms of thrombotic microangiopathy (TMA). Characteristic symptoms for HUS are TMA and renal failure, while TTP manifests with TMA, neurological symptoms, fever, and less commonly renal failure. Typical HUS is related to Shiga toxin producing Escherichia coli infection, while complement dysregulation leads to atypical HUS. Secondary HUS may be related to drugs, malignancies, pregnancy, and systemic disorders [2]. The severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity <5% causes TTP. TTP may be secondary to SLE.

Case report

We report the case of a 15-year-old girl, with an unremarkable family history. One year earlier, she suffered from malaise and hair loss. The diagnosis of autoimmuno-hemolytic anemia was established. After six months’ steroid treatment, relapse of anemia and decreased platelet count were observed due to cytomegalovirus infection. She was treated with immunoglobulins and steroids. A month later she developed pain in the lower limbs. She was admitted to the hospital with generalized edema, butterfly patch on the face, blood pressure 105/65 mmHg, and urine output 240 ml/day. The neurological examination was negative. Laboratory investigations showed: hemoglobin 63 g/l, red blood cell count 2.08 × 1012/l; white blood cell count 3.2 × 109/l; platelet count 5.0 × 109/l, bilirubin total 53 μmol/l, LDH 2691 U/l, albumin 30 g/l; serum creatinine 229.89 μmol/l, eGFR 27 ml/min/1.73 m2 ; in urinalysis: proteinuria 6.5 g/l, erythrocyturia, and leukocyturia. Urine culture was negative. Peripheral blood smear showed schistocytes. The direct Coombs test was positive, warm antibodies (IgG) were detected. The serum complement components were: C3 < 0.40 g/l, C4 < 0.08 g/l. Antinuclear antibodies (ANA) 1 : 2560; anti-dsDNA antibody (++) and ADAMTS13 activity < 4% with the presence of ADAMTS13 inhibitor 62 UI/ml were detected. In renal biopsy, mesangial proliferation, karyorrhexis, capillary loops’ lobulization, infiltration of mononuclear cells in interstitium and mesangial deposition of C3 complement (+2/+3), IgA (+2/+3), IgM (+1/+2), IgG (+1) and fibrinogen (+1) were present. In electron microscopy, partial thickening of capillary loops, interposition of mesangium and electron dense mesangial, subepithelial, subendothelial, and intramembranous deposits were present. Lupus nephritis IVA/V was diagnosed [3]. There were no small thrombi in biopsy. She received 10 pulses of methylprednisolone 10 mg/kg/pulse IV and 6 pulses of cyclophosphamide 750 mg/m2/monthly IV, then for 2.5 years azathioprine with prednisone, chloroquine, and enalapril. After one month’s treatment normalization of ADAMTS13 activity (74%) and ADAMTS13 inhibitor (15 UI/ml) were observed, serum C3 0.56 g/l, C4 0.11 g/l; ANA 1 : 640, anti-dsDNA antibody (+), eGFR > 60 ml/min/1.73 m2 . Urinalysis was normal after 2 months. After three years of treatment: serum C3 0.90 g/l, serum C4 0.11 g/l, ANA 1 : 160, anti-dsDNA antibody (–), eGFR 94 ml/min/1.73 m2 , urinalysis is normal.

Discussion

In our patient with anemia, thrombocytopenia and acute renal injury, the peripheral blood smear showed schistocytes, thereby indicating microangiopathic anemia, and Coombs test was positive, which may suggest two coexisting mechanisms for the development of anemia (mechanic/TMA and antibodies/SLE). The laboratory tests showed high ANA titer and very low ADAMTS13 activity with the presence of ADAMTS13 inhibitor (antibodies), so TTP secondary to SLE was suspected. In renal biopsy, SLE nephritis was diagnosed; there were no small thrombi, but only 50-75% of SLE-related TTP patients revealed in biopsy the typical features of TMA. In SLE-related TTP, immunosuppression should be administered to control SLE activity, while plasmapheresis is considered controversial [4, 5]. In our patient with SLE and secondary TTP related to presence of the inhibitor ADAMTS13, intravenous CYP treatment with steroids was effective, without the need of plasmapheresis.

Conclusions

In patient with SLE presenting with anemia, thrombocytopenia, and acute kidney injury, secondary TTP/HUS should be suspected and the presence of ADAMTS13 inhibitor and the ADAMTS13 activity should be tested to ensure the right therapeutic decisions. The prognosis of patients with SLE-related TTP may be good, despite very low ADAMTS13 activity, provided that immunosuppressive treatment is aggressive.
  5 in total

Review 1.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

2.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Authors:  Michelle Petri; Ana-Maria Orbai; Graciela S Alarcón; Caroline Gordon; Joan T Merrill; Paul R Fortin; Ian N Bruce; David Isenberg; Daniel J Wallace; Ola Nived; Gunnar Sturfelt; Rosalind Ramsey-Goldman; Sang-Cheol Bae; John G Hanly; Jorge Sánchez-Guerrero; Ann Clarke; Cynthia Aranow; Susan Manzi; Murray Urowitz; Dafna Gladman; Kenneth Kalunian; Melissa Costner; Victoria P Werth; Asad Zoma; Sasha Bernatsky; Guillermo Ruiz-Irastorza; Munther A Khamashta; Soren Jacobsen; Jill P Buyon; Peter Maddison; Mary Anne Dooley; Ronald F van Vollenhoven; Ellen Ginzler; Thomas Stoll; Christine Peschken; Joseph L Jorizzo; Jeffrey P Callen; S Sam Lim; Barri J Fessler; Murat Inanc; Diane L Kamen; Anisur Rahman; Kristjan Steinsson; Andrew G Franks; Lisa Sigler; Suhail Hameed; Hong Fang; Ngoc Pham; Robin Brey; Michael H Weisman; Gerald McGwin; Laurence S Magder
Journal:  Arthritis Rheum       Date:  2012-08

Review 3.  Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case and review.

Authors:  A Sakarcan; J Stallworth
Journal:  Pediatr Nephrol       Date:  2001-08       Impact factor: 3.714

Review 4.  The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Authors:  Jan J Weening; Vivette D D'Agati; Melvin M Schwartz; Surya V Seshan; Charles E Alpers; Gerald B Appel; James E Balow; Jan A Bruijn; Terence Cook; Franco Ferrario; Agnes B Fogo; Ellen M Ginzler; Lee Hebert; Gary Hill; Prue Hill; J Charles Jennette; Norella C Kong; Philippe Lesavre; Michael Lockshin; Lai-Meng Looi; Hirofumi Makino; Luiz A Moura; Michio Nagata
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612

5.  Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Authors:  George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.